Humoral and Cellular Immune Responses of People Living With Human Immunodeficiency Virus After 3 Doses of Messenger RNA BNT162b2 Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine: A Prospective Cohort Study.
Luba TauDavid HaginTal FreundTamar HalperinAmos AdlerRotem MaromSvetlana AhsanovNatasha MatusInbar LeviGal GerberShir LevTomer Ziv-BaranDan TurnerPublished in: Open forum infectious diseases (2023)
The anti-RBD IgG level after 3 doses of mRNA BNT162b2 vaccine was higher than the level after 2 doses, suggesting additional value of the booster. Cellular response did not further increase after a booster.